Fintel reports that on February 7, 2025, Piper Sandler upgraded their outlook for Nevro (NYSE:NVRO) from Underweight to ...

Nevro (NVRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Jefferies upgraded Nevro (NVRO) to Hold from Underperform with a price target of $5.85, up from $4.50, after the company entered into a ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

Globus Medical (GMED) and Nevro Corp. (NVRO) have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, ...

2-Year U.S. Treasury Note Continuous Contract $102.871 0.023 0.02% 5-Year U.S. Treasury Note Continuous Contract $106.664 0.094 0.09% 10-Year U.S. Treasury Note Continuous Contract $109.375 0.172 ...

2-Year U.S. Treasury Note Continuous Contract $102.695-0.168-0.16% 5-Year U.S. Treasury Note Continuous Contract $106.406-0.328-0.31% 10-Year U.S. Treasury Note Continuous Contract $109.156-0.422 ...

Globus Medical, a leading musculoskeletal solutions company, has announced its acquisition of Nevro Corp, a global medical ...